The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2011Defining PARKIN Substrates Through Systematic Quantitative Proteomics
Objective/Rationale:
The PARK2 (Parkin) gene is frequently mutated in Parkinson’s disease. Several lines of evidence indicate that Parkin functions to catalyze the conjugation of the small protein... -
MJFF Research Grant, 2011Modulation of Striatal Colinergic Neuronal Activity in LID
Objective/Rationale:
The role of striatal cholinergic interneurons (ChIs) in Parkinson’s disease and side effects of treatment like levodopa-induced dyskinesia (LID) have been poorly studied. We have... -
Rapid Response Innovation Awards, 2011Intestinal Microbiota, Permeability and Alpha-synclein Aggregation in Parkinson's Disease
Objective/Rationale:
Changes in the intestinal system may occur early in the development of Parkinson’s disease. The intestinal system is important to (1) maintain normal “healthy” bacteria; and (2)... -
Rapid Response Innovation Awards, 2011Alpha-Synuclein Knockdown: Therapeutic or Toxic?
Objective/Rationale:
The protein alpha-synuclein (a-syn) has been conclusively linked to Parkinson’s disease. The prevailing theory today states that a-syn is a causative agent in the development of... -
Improving Levodopa Delivery, 2011Dry Powder-Based Delivery of Intrapulmonary Levodopa as a Treatment for Motor Fluctuations in Parkinson's Disease
Objective/Rationale:
Oral levodopa pharmacokinetics are subject to excessive within- and between-subject variability, reflecting challenges inherent to gastrointestinal delivery. Aerosol delivery of... -
LRRK2, 2011LRRK2 Physiology in Parkinson's Disease
Objective/Rationale:
Mutations in the LRRK2 gene are a common cause of genetic Parkinson’s disease. LRRK2 is highly expressed in circulating and tissue immune cells. We have recently identified that...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.